Antibody avidity

[키워드] analyzed anti-RBD Anti-RBD IgG anti-RBD IgG4 antibody Antibody avidity antibody levels Antibody Response Applied immunology assessment association avidity avidity range Brazil COVID-19 detectable Diagnostic markers died disease effort elicit ELISA exacerbated Follow-up form Health highlighting hospitalized patient hospitalized patients house IgG IgG antibody IgG subclasse IgG1 IgG3 IgG4 Immunological response Immunological techniques indicate infected patient Laboratory less life-threatening Mild Mild disease Most patients outcome Patient predict protective immunity RBD RBD IgG RBD IgG-ELISA RBD protein resulting reveal SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RBD sensibility sera severe COVID-19 specificity study period symptomatic patient Symptomatic patients symptoms onset the disease Vaccine development with COVID-19 with mild disease
[DOI] 10.1038/s41598-021-95045-z PMC 바로가기 [Article Type] Clinical Trial